The share price of GUD has declined over the years, while its fundamentals have been mixed. The company maintains a very strong balance sheet and has grown its top line nicely, but its profits have declined over the years leading to a questionable outlook. GUD has been a disappointment for many, us included. Due to some of its fundamentals maintaining their strength (balance sheet, revenue growth), we have kept it in our coverage list, however, we feel it has been held long enough and with declining margins, we are dropping coverage on Knight Therapeutics (GUD).

LNF is well-run by such a shareholder-friendly management team with strong insider ownership, LNF has a solid record of consistently returning capital to shareholders through dividend increases, special dividends and aggressive buybacks. We are maintaining the rating at “B+”, while at the same time remaining open for a future downgrade if same-store sales do not improve.

ATS is an automation solutions provider to many of the world's largest companies. ATS remains uniquely positioned to capitalize on the ongoing efforts of its customers to enhance supply chain stability and visibility. Rating upgraded to 'B+'.